BRPI1012302A2 - composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho - Google Patents

composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho

Info

Publication number
BRPI1012302A2
BRPI1012302A2 BRPI1012302A BRPI1012302A BRPI1012302A2 BR PI1012302 A2 BRPI1012302 A2 BR PI1012302A2 BR PI1012302 A BRPI1012302 A BR PI1012302A BR PI1012302 A BRPI1012302 A BR PI1012302A BR PI1012302 A2 BRPI1012302 A2 BR PI1012302A2
Authority
BR
Brazil
Prior art keywords
rtki
eye
release
pharmaceutical composition
tyrosine kinase
Prior art date
Application number
BRPI1012302A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhagwati P Kabra
Malay Ghosh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI1012302A2 publication Critical patent/BRPI1012302A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1012302A 2009-03-03 2010-03-03 composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho BRPI1012302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
BRPI1012302A2 true BRPI1012302A2 (pt) 2015-09-22

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012302A BRPI1012302A2 (pt) 2009-03-03 2010-03-03 composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho

Country Status (12)

Country Link
US (2) US20100227905A1 (enExample)
EP (1) EP2403335B1 (enExample)
JP (1) JP5583146B2 (enExample)
KR (2) KR20110130454A (enExample)
CN (1) CN102340991B (enExample)
AU (1) AU2010221369B2 (enExample)
BR (1) BRPI1012302A2 (enExample)
CA (1) CA2753690A1 (enExample)
ES (1) ES2508290T3 (enExample)
MX (1) MX2011008731A (enExample)
WO (1) WO2010101992A1 (enExample)
ZA (1) ZA201105505B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2013019640A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
KR101811917B1 (ko) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
HK1208377A1 (en) 2012-05-04 2016-03-04 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
RU2646098C2 (ru) * 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
EP3233058A1 (en) 2014-12-15 2017-10-25 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
CN110662543A (zh) 2017-03-23 2020-01-07 灰色视觉公司 用于治疗眼部疾病的药物和组合物
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
EP4065131B1 (en) * 2019-11-28 2024-09-18 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2153234C (en) * 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
EP0842663A4 (en) * 1996-05-07 2003-06-18 Toray Industries OPHTHALMIC PREPARATIONS
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070148225A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
BRPI0721885A2 (pt) * 2007-07-20 2014-02-25 Alcon Inc Formulação farmacêutica para distribuição de compostos inibidores de receptores de tirosina quinase (rtki) para os olhos

Also Published As

Publication number Publication date
AU2010221369A1 (en) 2011-08-25
CA2753690A1 (en) 2010-09-10
KR20110130454A (ko) 2011-12-05
US20130137741A1 (en) 2013-05-30
MX2011008731A (es) 2011-09-29
US20100227905A1 (en) 2010-09-09
EP2403335A1 (en) 2012-01-11
EP2403335A4 (en) 2012-08-29
JP5583146B2 (ja) 2014-09-03
AU2010221369B2 (en) 2014-03-13
WO2010101992A1 (en) 2010-09-10
ES2508290T3 (es) 2014-10-16
EP2403335B1 (en) 2014-08-20
ZA201105505B (en) 2013-10-30
KR20160135372A (ko) 2016-11-25
JP2012519694A (ja) 2012-08-30
CN102340991A (zh) 2012-02-01
CN102340991B (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
BRPI1012302A2 (pt) composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
BRPI1008920A2 (pt) Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
ZA201201627B (en) Compounds as tyrosine kinase modulators
PT2435030E (pt) Composições farmacêuticas flutuantes de libertação controlada
BRPI0911988A2 (pt) micelas para liberação intracelular de agentes terapêuticos.
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
EP2453877A4 (en) MEDICAMENT COMPOSITION WITH DELAYED RELEASE
BR112012004525A2 (pt) composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
BR112013002096A2 (pt) compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
DOS2009000151S (es) Pantallas para dispensadores de pastillas / (parte de)
EP2445891A4 (en) 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS
HRP20181854T1 (hr) Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica
EP2231152A4 (en) THIENOPYRANONE AS A KINASEHEMMER
EP2160184A4 (en) HYPER-COMPRESSED PARTICLES FOR THE CONTROLLED RELEASE OF OPHTHALMIC MEDICAMENTS
BRPI0923003A2 (pt) composição de liberação controlada para produção de uma preparação de liberação prolongada contendo udenafil
BRPI0921210A2 (pt) processos para a preparação de compostos de arilaminas
AU2007356856A1 (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKI) compounds to the eye
BRPI0922623A2 (pt) comprimido farmacêutico de liberação controlada
PT2391352T (pt) Formas farmacêuticas para a libertação de compostos ativos
EP2445892A4 (en) 5-LOW HETEROARYL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS
PL2219611T3 (pl) Farmaceutyczne postacie do uwalniania związków czynnych

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]